Parkinsonism Clinical Trial
Official title:
Proactive and Integrated Management and Empowerment in Parkinson's Disease (PRIME-UK): A New Model of Care
People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life. Symptoms emerge and evolve as the disease progresses. Current care models are often inadequate to meet their needs. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care.
Background: People living with Parkinson's disease experience progressive motor and non-motor symptoms, which negatively impact on health-related quality of life and can lead to an increased risk of hospitalisation. It is increasingly recognised that the current care models are not suitable for the needs of people with parkinsonism whose care needs evolve and change as the disease progresses. This study aims to evaluate whether a complex and innovative model of integrated care will increase an individual's ability to achieve their personal goals, have a positive impact on health and symptom burden, and be more cost-effective when compared with usual care. Methods: This is a single centre, randomised controlled trial where people with parkinsonism and their informal caregivers are randomised into one of two groups: either PRIME Parkinson multi-component model of care; or usual care. Adults ≥18 years with a diagnosis of parkinsonism, able to provide informed consent or the availability of a close friend or relative to act as a personal consultee if capacity to do so is absent, and living in the trial geographical area are eligible. Up to three caregivers per patient can also take part, must be ≥18 years, provide informal, unpaid care and able to give informed consent. The primary outcome measure is goal attainment, as measured using the Bangor Goal Setting Interview. The duration of enrolment is 24 months. The total recruitment target is n=214 and the main analyses will be intention to treat. Discussion: This trial tests whether a novel model of care improves health and disease-related metrics including goal attainment, and decreases hospitalisations whilst being more cost-effective than the current usual care. Subject to successful implementation of this intervention within one centre, the PRIME Parkinson model of care could then be evaluated within a cluster-randomised trial at multiple centres. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02194816 -
Modifiable Variables in Parkinsonism (MVP)
|
||
Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
Enrolling by invitation |
NCT01453127 -
DaTSCAN Imaging in Aging and Neurodegenerative Disease
|
Phase 4 | |
Completed |
NCT01174771 -
Repetitive Transcranial Magnetic Stimulation (TMS) for Progressive Supranuclear Palsy and Corticobasal Degeneration
|
N/A | |
Completed |
NCT03314610 -
Effect of Need to Void on Parkinsonian Gait
|
||
Recruiting |
NCT05506891 -
Efficacy and Safety of Astragalus for Non-motor Symptoms of α-Synucleinopathy
|
Phase 2 | |
Completed |
NCT00950196 -
Amantadine for Improving Neurologic Symptoms in Ataxia-Telangiectasia
|
Phase 4 | |
Recruiting |
NCT03924414 -
Trial of Parkinson's And Zoledronic Acid
|
Phase 4 | |
Enrolling by invitation |
NCT05514106 -
MIBG in Aging and Neurologic Disorders
|
Phase 4 | |
Completed |
NCT01581645 -
Mobilaser Study to Help With People Who Are Having Problems With Their Gait
|
Phase 0 | |
Not yet recruiting |
NCT00767546 -
Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients
|
Phase 1 | |
Completed |
NCT02214862 -
2-(1-{6-[(2-[F-18]Fluoroethyl) (Methyl)Amino]-2-naphthyl} Ethylidene) Malononitrile-PET for in Vivo Diagnose of Tauopathy in Unclassified Parkinsonism
|
Phase 0 | |
Recruiting |
NCT04518059 -
Misfolded Proteins in the Skin of People With Parkinson's Disease and Other Parkinsonism
|
||
Completed |
NCT03076671 -
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
|
N/A | |
Withdrawn |
NCT01329926 -
Molecular Analysis of Human Neural Stem Cells
|
||
Terminated |
NCT00745030 -
Efficacy and Tolerability of Ramelteon in Patients With Rapid Eye Movement (REM) Behavior Disorder and Parkinsonism
|
N/A | |
Completed |
NCT04222218 -
Cerebellar rTMS Theta Burst for Postural Instability in Progressive Supranuclear Palsy
|
N/A | |
Completed |
NCT03386669 -
Novel Neuroimage Study in Tauopathies With Parkinsonism
|
Phase 2 | |
Completed |
NCT02064543 -
Measurement of Gait Using Opal APDM and Gait Mat in Parkinsonism
|
||
Active, not recruiting |
NCT05308485 -
Events Exposure as a Trigger of the Clinical Manifestations of Parkinson's Disease
|